Evidence map›Paper›PMID 23329885›Full record

Trial reportInternational journal of medical sciences2013

Creatine metabolism and safety profiles after six-week oral guanidinoacetic acid administration in healthy humans.

Sergej M Ostojic, Barbara Niess, Marko Stojanovic, Milos Obrenovic

2 registry-linked trialsOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in International journal of medical sciences, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01133899 phase1 / phase2completednot on this map

The Effects of Medium-term Oral Guanidinoacetic Acid (GAA) Administration on Human Performance, Body Composition, and Metabolic Outcomes in Physically Active Men and Women

TypeinterventionalSponsorMetropolitan University, SerbiaRan2010 to 2011Enrolled40ConditionsAthletic PerformanceArmsguanidinoacetic acid, GAA-4, GAA-1, PLACEBO
NCT02213679 nacompletednot on this mapstarted 2014, after this paper: background citation

Guanidinoacetic Acid Loading for Chronic Fatigue Syndrome

TypeinterventionalSponsorCenter for Health Sciences, SerbiaRan2014 to 2015Enrolled20ConditionsChronic Fatigue SyndromeArmsGuanidinoacetic acid, Placebo
3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 56 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Cellular bioenergetics of guanidinoacetic acid: the role of mitochondria.Journal of bioenergetics and biomembranes · 2015
    Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Sergej M OstojicCenter for Health, Exercise and Sport Sciences, Belgrade, Serbia. sergej.ostojic@chess.edu.rs
Barbara Niess
Marko Stojanovic
Milos Obrenovic
Center for Health, Exercise and Sport Sciences · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesGuanidinoacetic acid (GAA) is a natural precursor of creatine, yet the potential use of GAA as a nutritional additive for restoring creatine availability in humans has been limited by unclear efficacy and safety after exogenous GAA administration. The present study evaluated the effects of orally administered GAA on serum and urinary GAA, creatine and creatinine concentration, and on the occurrence of adverse events in healthy humans. METHODS AND

resultsTwenty-four healthy volunteers were randomized in a double-blind design to receive either GAA (2.4 grams daily) or placebo (PLA) by oral administration for 6 weeks. CLINICAL

trial registrationwww.clinicaltrials.gov, identification number NCT01133899. Serum creatine and creatinine increased significantly from before to after administration in GAA-supplemented participants (P < 0.05). The proportion of participants who reported minor side effects was 58.3% in the GAA group and 45.5% in the placebo group (P = 0.68). A few participants experienced serum creatine levels above 70 µmol/L.

conclusionExogenous GAA is metabolized to creatine, resulting in a significant increase of fasting serum creatine after intervention. GAA had an acceptable side-effects profile with a low incidence of biochemical abnormalities.

Indexed as

Administration, OralAdultCreatineCreatinineDietary SupplementsFemaleGlycineHumansMaleCreatineCreatinineGlycineglycocyamineClinical markers.Creatine synthesisCreatinine

Identifiers

PMID23329885
PMCPMC3547211
OpenAlexW2112894167

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.